This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ferone, D. Articles by Lombardi, G. Search for Related Content PubMed PubMed Citation Articles by Ferone, D. Articles by Lombardi, G. Pubmed/NCBI databases Compound via MeSH Substance via MeSH

Correlation of Scintigraphic Results Using ¹²³I-Methoxybenzamide with Hormone Levels and Tumor Size Response to Quinagolide in Patients with Pituitary Adenomas

Department of Molecular and Clinical Endocrinology and Oncology, "Federico II" University (D.F., A.C., G.C., B.M., G.L.), Department of Nuclear Medicine, National Cancer Institute, "Fondazione G. Pascale" (S.L., P.V., W.A.), CNR (M.S.), 080131 Naples, Italy.

Address all correspondence and requests for reprints to: Annamaria Colao, M.D., Ph.D., Department of Molecular and Clinical Endocrinology and Oncology, "Federico II" University, via S. Pansinis, 80131 Naples, Italy.

The efficacy of dopaminergic agents in the medical treatment of pituitary adenomas is well known. Quinagolide is a nonergot derivative dopamine agonist, which binds dopamine D₂ receptors with high affinity. The treatment with this drug is reported to suppress hormone levels and to cause tumor shrinkage in prolactinomas and in a few GH-secreting pituitary adenomas. In clinically nonfunctioning pituitary adenomas (NFPA), the efficacy of quinagolide treatment is controversial. The scintigraphy of the pituitary region using ¹²³I-methoxybenzamide (¹²³I-IBZM) allows us to visualize in vivo the expression of dopamine D₂ receptors on pituitary tumors.

In this study, the pituitary scintigraphy with ¹²³I-IBZM was performed in 14 patients with macroadenoma before starting a long-term treatment with quinagolide: 6 NFPA with high circulating -subunit levels, 4 PRL-secreting, and 4 GH-secreting adenomas. A 3-point score was used to grade the ligand accumulation within the pituitary adenomas: 0 = negative, 1 = moderate uptake (equal to that recorded in the cerebral cortex), and 2 = intense uptake (equal to that recorded in the basal nuclei). The treatment with quinagolide was carried out at the dose of 0.3–0.6 mg/day for 6–12 months. Clinical, biochemical and hormonal assessment was repeated monthly during the first 3 months, then quarterly. Sellar magnetic resonance imaging was performed before and after 6 and 12 months of quinagolide treatment, to evaluate tumor shrinkage (>25% of baseline size).

In all 14 patients, a significant positive correlation was found between the degree of ¹²³I-IBZM uptake and the clinical response to quinagolide treatment (r = 0.90; P < 0.001). In particular, the normalization of serum -subunit and PRL levels, respectively, was achieved in 3 patients with NFPA and in 2 patients with prolactinoma, who showed intense ¹²³I-IBZM uptake in the pituitary region. In 4 of these 5 patients with positive scan, a significant tumor shrinkage occurred between 6 and 12 months after the beginning of quinagolide treatment. In all patients with GH-secreting adenoma, no significant uptake of ¹²³I-IBZM was found and no significant decrease of circulating GH and/or insulin-like growth factor-I levels, and tumor shrinkage was obtained during long-term treatment with quinagolide.

In conclusion, the pituitary scintigraphy with ¹²³I-IBZM can be considered a useful tool to indicate adenomas with significant expression of functioning D₂ receptors. This innovative technique may predict the response to long-term treatment with quinagolide in patients with NFPA, where the lack of pituitary hormone hypersecretion makes difficult the monitoring of medical treatment efficacy.

This article has been cited by other articles:

				D. Ferone, R. Pivonello, E. Resmini, M. Boschetti, A. Rebora, M. Albertelli, V. Albanese, A. Colao, M. D Culler, and F. Minuto Preclinical and clinical experiences with the role of dopamine receptors in the treatment of pituitary adenomas Eur. J. Endocrinol., April 1, 2007; 156(suppl_1): S37 - S43. [Abstract] [Full Text] [PDF]

				W. W de Herder, A. E M Reijs, R. A Feelders, M. O van Aken, E. P Krenning, A.-J. van der Lely, and D. J Kwekkeboom Diagnostic imaging of dopamine receptors in pituitary adenomas Eur. J. Endocrinol., April 1, 2007; 156(suppl_1): S53 - S56. [Abstract] [Full Text] [PDF]

				A. Colao, M. Filippella, R. Pivonello, C. Di Somma, A. Faggiano, and G. Lombardi Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours Eur. J. Endocrinol., April 1, 2007; 156(suppl_1): S57 - S63. [Abstract] [Full Text] [PDF]

				W. W de Herder, A. E M Reijs, R. A Feelders, M. O van Aken, E. P Krenning, H. L J Tanghe, A.-J. van der Lely, and D. J Kwekkeboom Dopamine agonist therapy of clinically non-functioning pituitary macroadenomas. Is there a role for 123I-epidepride dopamine D2 receptor imaging? Eur. J. Endocrinol., November 1, 2006; 155(5): 717 - 723. [Abstract] [Full Text] [PDF]

				R. Pivonello, C. Matrone, M. Filippella, L. M. Cavallo, C. Di Somma, P. Cappabianca, A. Colao, L. Annunziato, and G. Lombardi Dopamine Receptor Expression and Function in Clinically Nonfunctioning Pituitary Tumors: Comparison with the Effectiveness of Cabergoline Treatment J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1674 - 1683. [Abstract] [Full Text] [PDF]